Ads
related to: common dosage for atorvastatin
Search results
Results From The WOW.Com Content Network
Atorvastatin, sold under the brand name Lipitor among others, is a statin medication used to prevent cardiovascular disease in those at high risk and to treat abnormal lipid levels. [6] For the prevention of cardiovascular disease, statins are a first-line treatment in reducing cholesterol. [6] It is taken by mouth. [6]
A common variation in this gene was found in 2008 to significantly increase the risk of myopathy. [99] Records exist of over 250,000 people treated from 1998 to 2001 with the statin drugs atorvastatin, cerivastatin, fluvastatin, lovastatin, pravastatin, and simvastatin. [100]
It is also available in the fixed-dose combinations ezetimibe/simvastatin, [6] ezetimibe/atorvastatin, [7] ezetimibe/rosuvastatin, [4] [8] and ezetimibe/bempedoic acid. [9] The most commonly reported adverse events include upper respiratory tract infections, joint pain, diarrhea, and tiredness. [4]
Ezetimibe/atorvastatin (trade names Liptruzet, Atozet) is a cholesterol lowering combination drug. In the United States, it was approved in May 2013, by the Food and Drug Administration for the treatment of elevated low-density lipoprotein (LDL) in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet. [ 1 ]
Statins are linked to better health outcomes in older adults over the age of 70 with or without previous cardiovascular disease, a new study finds.
Lipid-lowering agents, also sometimes referred to as hypolipidemic agents, cholesterol-lowering drugs, or antihyperlipidemic agents are a diverse group of pharmaceuticals that are used to lower the level of lipids and lipoproteins, such as cholesterol, in the blood (hyperlipidemia).
Increase the dose in increments of 500 milligrams weekly or 850 milligrams every one to two weeks, up to a maximum dose of 2,550 milligrams per day, taken in divided doses.
In five RCTs a mean atorvastatin dose of 26 mg/day reduced LDL cholesterol by 44.0% and reduced myocardial infarction, relative risk, 0.67 (95% CI 0.58 to 0.77) as compared to placebo. In four RCTs a mean rosuvastatin dose of 16 mg/day reduced LDL cholesterol by 48.8% and reduced myocardial infarction, relative risk, 0.82 (95% CI 0.73 to 0.93 ...